Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 August 2025 | Story Martinette Brits
Dr Tlou Raphela-Masuku
Dr Tlou Raphela-Masuku, Senior Lecturer in the UFS Disaster Management Training and Education Centre for Africa (DiMTEC), was selected as one of 15 early-career researchers from Southern and Eastern Africa to join the British Academy-funded International Writing Workshop on Climate Change Adaptation.

Dr Tlou Raphela-Masuku, Senior Lecturer in the University of the Free State (UFS) Disaster Management Training and Education Centre for Africa (DiMTEC), has been selected as one of only 15 early-career researchers from Southern and Eastern Africa to participate in the prestigious British Academy-funded International Writing Workshop on Climate Change Adaptation.

Her selection follows a highly competitive process involving applicants from across the region, underscoring her growing influence in climate research. “Being selected as one of only 15 early-career researchers from the SADC and East Africa region was truly humbling. It affirmed the value of my research and passion for climate adaptation and further motivated me to keep making a meaningful contribution in this field,” she said.

 

Strengthening research visibility and collaboration

The workshop is jointly organised by York St John University (UK), the University of the West of England (UK), the University of Nairobi (Kenya), and the University of Cape Town (South Africa). It brings together emerging scholars from a range of disciplinary backgrounds to foster interdisciplinary collaboration, strengthen academic writing and publishing skills, and develop grant proposal expertise.

For Dr Raphela-Masuku, the programme is a natural fit with her work at DiMTEC. “At DiMTEC, my work spans ecosystem-based disaster risk reduction and climate change adaptation. I am the core teacher for this module for master’s students. My recent and upcoming research, including work on flood risks and climate vulnerability among subsistence farmers, directly aligns with the themes of the workshop,” she explained.

Her focus within the programme will be on climate-induced vulnerabilities and resilience, particularly in rural and peri-urban communities, with a strong emphasis on extreme weather events and nature-based solutions. She looks forward to both the online and in-person engagements in Nairobi and Cape Town, which will run between 2025 and 2027. “These offer a fantastic opportunity for peer learning, mentorship, and deeper engagement with fellow climate researchers. Exchanging ideas face to face is always energising and often leads to lasting collaborations,” she said.

 

Advancing DiMTEC’s mission

Participation in the workshop will not only advance Dr Raphela-Masuku’s own academic profile but also strengthen DiMTEC’s regional and continental footprint. “My participation directly supports DiMTEC’s mission to build climate resilience and disaster preparedness across Africa. It strengthens our footprint in the region and facilitates collaboration with other institutions working on similar challenges, especially in rural vulnerability and adaptation,” she noted.

She sees the experience as a vital platform to amplify her work on flood resilience and the health impacts of climate change to audiences that include academics, policymakers, and practitioners. “The workshop will enhance the visibility of my work and provide the tools and strategies to navigate high-impact publishing, which is crucial for emerging African scholars,” she added.

Reflecting on her journey, Dr Raphela-Masuku said it has been “rooted in both academic enquiry and real-world impact”, driven by the urgent need to support vulnerable communities. Her advice to aspiring researchers is clear: “Stay curious. Stay rooted in the needs of your communities. And don’t be afraid to ask hard questions or chase ambitious goals. Climate adaptation research is not just about publishing papers – it’s about finding real solutions for real people.”

News Archive

Research contributes to improving quality of life for cancer patients
2016-11-21

Description: Inorganic Chemistry supervisors  Tags: Inorganic Chemistry supervisors

Inorganic Chemistry supervisors in the Radiopharmacy
Laboratory during the preparation of a typical complex
mixture to see how fast it reacts. Here are, from the left,
front: Dr Marietjie Schutte-Smith, Dr Alice Brink
(both scholars from the UFS Prestige
Scholar Programme), and Dr Truidie Venter (all three
are Thuthuka-funded researchers).
Back: Prof André Roodt and Dr Johan Venter.
Photo: Supplied

Imagine that you have been diagnosed with bone cancer and only have six months to live. You are in a wheelchair because the pain in your legs is so immense that you can’t walk anymore – similar to a mechanism eating your bones from the inside.

You are lucky though, since you could be injected with a drug to control the pain so effective that you will be able to get out of the wheelchair within a day-and-a-half and be able to walk again. Real-life incidents like these provide intense job satisfaction to Prof André Roodt, Head of Inorganic Chemistry at the University of the Free State (UFS). The research, which is conducted by the Inorganic Group at the UFS, contributes greatly to the availability of pain therapy that does not involve drugs, but improves the quality of life for cancer patients.

The research conducted by the Inorganic Group under the leadership of Prof Roodt, plays a major role in the clever design of model medicines to better detect and treat cancer.

The Department of Chemistry is one of approximately 10 institutions worldwide that conducts research on chemical mechanisms to identify and control cancer. “The fact that we are able to cooperate with the Departments of Nuclear Medicine and Medical Physics at the UFS, the Animal Research Centre, and other collaborators in South Africa and abroad, but especially the methodology we utilise to conduct research (studying the chemical manner in which drugs are absorbed in cancer as well as the time involved), enhances the possibility of making a contribution to cancer research,” says Prof Roodt.

Technique to detect cancer spots on bone
According to the professor, there are various ways of detecting cancer in the body. Cancer can, inter alia, be identified by analysing blood, X-rays (external) or through an internal technique where the patient is injected with a radioactive isotope.

Prof Roodt explains: “The doctor suspects that the patient has bone cancer and injects the person with a drug consisting of an isotope (only emits X-rays and does no damage to tissue) that is connected to a phosphonate (similar to those used for osteoporosis). Once the drug is injected, the isotope (Technetium-99m) moves to the spot on the bone where the cancer is located. The gamma rays in the isotope illuminate the area and the doctor can see exactly where treatment should be applied. The Technetium-99m has the same intensity gamma rays as normal X-rays and therefore operates the same as an internal X-ray supply.” With this technique, the doctor can see where the cancer spots are within a few hours.

The same technique can be used to identify inactive parts of the brain in Alzheimer patients, as well as areas of the heart where there is no blood supply or where the heart muscle is dead.

Therapeutic irradiation of cancer
For the treatment of pain connected with cancer, the isotope Rhenium-186 is injected. Similar to the manner in which the Technetium-99m phosphonate compound is ingested into the body, the Rhenium-186 phosphonate travels to the cancer spots. Patients thus receive therapeutic irradiation – a technique known as palliative therapy, which is excellent for treating pain. A dosage of this therapy usually lasts for about two months.

The therapy is, however, patient specific. The dosages should correspond with the occurrence and size of cancer spots in the patient’s body. First, the location of the cancer will be determined by means of a technetium scan. After that, the size of the area where the cancer occurs has to be determined. The dosage for addressing total pain distribution will be calculated according to these results.

Technique to detect cancer spots on soft tissue
Another technique to detect cancer as spots on bone or in soft tissue and organs throughout the body is by utilising a different type of irradiation, a so-called PET isotope. The Fluor-18 isotope is currently used widely, and in Pretoria a machine called a cyclotron was produced by Dr Gerdus Kemp, who is a former PhD graduate from the Inorganic Research Group. The F-18 is then hidden within a glucose molecule and a patient will be injected with the drug after being tranquillised and after the metabolism has been lowered considerably. The glucose, which is the ‘food' that cancer needs to grow, will then travel directly to the cancer area and the specific area where the cancer is located will thus be traced and ‘illuminated’ by the Fluor-18, which emits its own 'X-rays'.

In the late 80s, Prof Roodt did his own postdoctoral study on this research in the US. He started collaborating with the Department of Nuclear Medicine at the UFS in the early 90s, when he initiated testing for this research.

Through their research of more than 15 years, the Inorganic Group in the Department of Chemistry has made a major contribution to cancer research. Research on mechanisms for the detection of cancer, by designing new clever chemical agents, and the chemical ways in which these agents are taken up in the body, especially contributes to the development in terms of cancer therapy and imaging, and has been used by a number of hospitals in South Africa.

The future holds great promise
Prof Roodt and his team are already working on a bilateral study between the UFS and Kenya. It involves the linking of radio isotopes, as mentioned above, to known natural products (such as rooibos tea), which possess anti-cancer qualities.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept